Press release
Duchenne Muscular Dystrophy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Li
Duchenne Muscular Dystrophy Pipeline Analysis
According to DelveInsight, over 75 leading companies are actively engaged in developing more than 75 treatment therapies for Duchenne Muscular Dystrophy, reflecting a strong and ongoing pipeline effort.
Duchenne Muscular Dystrophy Overview:
Duchenne muscular dystrophy (DMD) is a severe inherited neuromuscular disorder and the most prevalent type of muscular dystrophy worldwide, affecting individuals across all races and ethnicities. It is caused by mutations in the dystrophin gene, leading to progressive muscle weakness and degeneration. Symptoms typically begin with difficulty walking and progressively worsen, eventually resulting in loss of mobility and dependence on a wheelchair. Patients often experience cardiac and orthopedic complications, and most succumb to the disease in their twenties due to respiratory failure or cardiomyopathy. Current treatments, such as glucocorticoids and physiotherapy, aim to slow disease progression and manage symptoms.
Dystrophin is a vital cytoskeletal protein that connects the muscle cell structure to its surrounding matrix via the dystrophin-glycoprotein complex (DGC). This complex helps stabilize muscle fibers during contraction. In DMD, the absence of dystrophin and DGC proteins leads to fragile cell membranes, disrupted calcium balance, and increased oxidative stress, all of which contribute to muscle cell damage and death. Over time, as muscle regeneration declines, functional muscle tissue is replaced by connective and fat tissue, leading to further decline in muscle function.
Request for a detailed insights report on Duchenne Muscular Dystrophy pipeline insights [https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Duchenne Muscular Dystrophy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Duchenne Muscular Dystrophy Therapeutics Market.
Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report
*
DelveInsight's Duchenne Muscular Dystrophy (DMD) pipeline report highlights a strong and evolving landscape, with over 75 active companies working on more than 75 potential therapies for DMD treatment.
*
In June 2024, REGENXBIO Inc. began enrolling boys aged 1 to 3 years in its Phase I/II AFFINITY DUCHENNE Registered trial, aimed at evaluating the safety and efficacy of RGX-202, a gene therapy for DMD.
*
Leading companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences, FibroGen, Edgewise Therapeutics (EDG-5506), Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, and Hansa Biopharma are actively advancing novel therapies to enhance the DMD treatment landscape.
*
Promising candidates in the pipeline include Vamorolone, Givinostat, Pamrevlumab, among others, spanning various stages of clinical development.
Duchenne Muscular Dystrophy Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Duchenne Muscular Dystrophy Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Duchenne Muscular Dystrophy market.
Download our free sample page report on Duchenne Muscular Dystrophy pipeline insights [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Duchenne Muscular Dystrophy Emerging Drugs
*
Vamorolone: Santhera
*
Givinostat: Italfarmaco
*
Pamrevlumab: Fibrogen
Duchenne Muscular Dystrophy Companies
More than 75 major companies are actively developing treatments for Duchenne Muscular Dystrophy. Among them, Roche has drug candidates that have progressed to the most advanced stage of development, Phase III clinical trials.
DelveInsight's report covers around 75+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Duchenne Muscular Dystrophy Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Duchenne Muscular Dystrophy Therapies and Key Companies: Duchenne Muscular Dystrophy Clinical Trials and advancements [https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Duchenne Muscular Dystrophy Pipeline Therapeutic Assessment
- Duchenne Muscular Dystrophy Assessment by Product Type
- Duchenne Muscular Dystrophy By Stage
- Duchenne Muscular Dystrophy Assessment by Route of Administration
- Duchenne Muscular Dystrophy Assessment by Molecule Type
Download Duchenne Muscular Dystrophy Sample report to know in detail about the Duchenne Muscular Dystrophy treatment market @ Duchenne Muscular Dystrophy Therapeutic Assessment [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Duchenne Muscular Dystrophy Current Treatment Patterns
4. Duchenne Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Duchenne Muscular Dystrophy Late-Stage Products (Phase-III)
7. Duchenne Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Duchenne Muscular Dystrophy Discontinued Products
13. Duchenne Muscular Dystrophy Product Profiles
14. Duchenne Muscular Dystrophy Key Companies
15. Duchenne Muscular Dystrophy Key Products
16. Dormant and Discontinued Products
17. Duchenne Muscular Dystrophy Unmet Needs
18. Duchenne Muscular Dystrophy Future Perspectives
19. Duchenne Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Duchenne Muscular Dystrophy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=duchenne-muscular-dystrophy-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-analysis-santhera-pharmaceuticals-sarepta-therapeutics-italfarmaco-wave-li]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Li here
News-ID: 4105421 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Duchenne
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in the…
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…
